

The Novel Use of High-Dose Hydroxocobalamin for Vasoplegic Syndrome in a Pediatric **Patient after Cardiopulmonary Bypass**

Paras Patel MD, Jake Scott MD, Lindsey Loveland-Baptist MD, Stylianos Voulgarelis MD, George Hoffman MD **Department of Anesthesiology - Children's Hospital of Wisconsin – Medical College of Wisconsin**

Case

- 6 month old male with hypoplastic left heart syndrome (HLHS) who underwent a bidirectional Glenn procedure
- Exhibited severe hypoxia with elevated transpulmonary gradient secondary to a large thrombus extending from the left internal jugular vein to the innominate vein.
- Underwent thrombectomy on CPB, and required VA ECMO for persistently elevated BDG pressures, hypoxia, and cardiogenic shock

Perioperative Events

- Required significant vasoactive support while on ECMO and developed multiorgan system failure
- After weaning from CPB there was minimal vasoconstrictor response to norepinephrine, vasopressin and hydrocortisone.
- Vasoplegia persisted until <u>hydroxocobalamin (B12) was</u> administered in three divided doses of 70mg/kg IV.
- Hemodynamics improved after B12 administration and vasoconstrictor requirement was significantly reduced.
- He eventually developed oliguric renal failure, hyperkalemia, and persistent multiorgan failure.



Anesthetic Record

Table 1. Pre-B12 administration trends were consistent with distributive physiology. After B12 administration, vasoactive requirements decreased with evidence of increased SVR. As vasoconstrictor therapy was weaned, oxygen delivery based on non-invasive measures were improved.

Parameter	Pre-B12	30 min post B12
MAP (mmHg)	31	48
CVP (mmHg)	20	20
SpO2 (%)	71	81
rSO2C (%)	23	17
rSO2S (%)	63	43
PetCO2 (torr)	38	43
PP (mmHg)	11	28
Da-vO2 (%)	8	38
VI	108	48



Post-op	
41	
15	
79	
45	
58	
56	
55	
21	
40	

Discussion

- Vasoplegic syndrome incidence: 5% 15%.
- Risk factors: ACE inhibition, beta blockade, long CPB.
- Etiology: multifactorial, related to a dysfunction of nitric oxide mediated vascular smooth muscle resistance.
- Treatment: alpha-agonists, vasopressin, and nitric oxide scavengers like methylene blue.
- Methylene blue: hemolytic anemia, serotonin syndrome, methemoglobinemia, and pulse oximetry interference.
- Vitamin B12: for cyanide poisoning (70mg/kg IV) \rightarrow nontoxic cyanocobalamin, which is then excreted.
- Mechanism: nitric oxide and carbon monoxide scavenging.
- Side effects: hypertension, increased SVR, rash, erythema, dysphagia and chromaturia.
- Our patient: rash, chromaturia, and increased SVR
- VIS: evidence of increased SVR after administration of B12

Sources

- 1. Levin MA et al. Circulation 2009; 120:1664–71.
- Roderique JD, et al. Ann Thorac Surg 2014;97: 1785–6. 2.
- Burnes ML, et al. J Cardiothorac Vasc Anesth 2017; 31:1012-1014 3.
- Gerth K, et al. Clin Toxicol (Phila) 2006; 44(Suppl 1):29–36 4.